Back to News
Market Impact: 0.45
Revolution Medicines' Daraxonrasib Secures FDA Breakthrough Designation In Pancreatic Cancer
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
Revolution Medicines received FDA Breakthrough Therapy Designation for RASONQUE (daraxonrasib), its RAS(ON) multi-selective cancer therapy. The designation can expedite development and regulatory review, improving the drug's path toward commercialization and representing a positive catalyst for RVMD.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.65
Ticker Sentiment
RVMD0.82
More News
- China's AI leaders keep quiet despite U.S. 'publicity' on tech risks
- US Senate crypto bill collapses in blow to industry
- BlackRock’s Fink, Blackstone’s Gray Back Carney’s Canada Investment Push
- Factbox-How AI leaders and world governments react to ’AI doom’ fears
- ‘The end of the keyboard is near’: Christian Klein predicts voice translation will be the next workplace advantage
- Push for AI regulation mounts as talk of AI’s ‘existential’ risks go mainstream. But Trump resists calls for a slowdown